Zobrazeno 1 - 10
of 929
pro vyhledávání: '"I. Silverberg"'
Autor:
Jonathan I. Silverberg, David Rosmarin, Raj Chovatiya, Thomas Bieber, Stephen Schleicher, Lisa Beck, Melinda Gooderham, Sohail Chaudhry, Christie Fanton, Danni Yu, Joshua Levy, Yi Liu, Takahiro Miyazaki, Mary Tagliaferri, Carsten Schmitz, Ajay Nirula, Brian Kotzin, Jonathan Zalevsky
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Regulatory T cell (Treg) impairment is implicated in the pathogenesis of chronic inflammatory diseases, but relatively little is known about the therapeutic potential of Treg restoration. Here we present clinical evidence for the Treg-select
Externí odkaz:
https://doaj.org/article/9bc93354dab940bc992d2c583c1fb98c
Autor:
Eric Simpson, Peter Lio, Evangeline Pierce, Angel Cronin, Robert R. McLean, Thomas Eckmann, Amber Reck Atwater, Zach Dawson, Jonathan I. Silverberg
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1061-1075 (2024)
Abstract Background Atopic dermatitis (AD) is associated with patient burden, but few studies describe the anatomic distribution of the disease or the impact of number of lesion locations. Objectives To describe lesion locations and assess the relati
Externí odkaz:
https://doaj.org/article/1df801ec59644b639d7259309537b19e
Autor:
Jonathan I. Silverberg, Feifei Yang, Evo Alemao, Jing Zhao, Concetta Crivera, Hetal V. Patel, Iris Lin, Aaron R. Mangold
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1206-1211 (2024)
Abstract Background The potential association of long‐term oral corticosteroid (OCS) use with adverse events (AEs) in patients with bullous pemphigoid (BP) is not well characterized in a real‐world setting. Objectives To evaluate the effect of OC
Externí odkaz:
https://doaj.org/article/16ee0fb30da34575b66759ff2cd9c7a3
Autor:
Ross O’Hagan, MD, Samir Kamat, MD, Shira Wieder, MD, Marcel Perl, MD, Jonathan I. Silverberg, MD, PhD, MPH, Nanette B. Silverberg, MD
Publikováno v:
JAAD International, Vol 16, Iss , Pp 127-129 (2024)
Externí odkaz:
https://doaj.org/article/50f00e523a2a42728cbc2035a0173e99
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
Autor:
Andrew Blauvelt, Kilian Eyerich, Alan D. Irvine, Marjolein de Bruin-Weller, Shawn G. Kwatra, Melinda Gooderham, Brian Kim, Brian M. Calimlim, Wan-Ju Lee, Eliza M. Raymundo, Yingyi Liu, Sarah Ofori, Andrew M. Platt, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2621-2630 (2024)
Abstract Introduction Atopic dermatitis (AD), with its hallmark symptoms of pruritus and skin lesions, often impairs patients’ quality of life. We assessed time spent with clear/almost clear skin and no/minimal itch during upadacitinib treatment ve
Externí odkaz:
https://doaj.org/article/f20cd55b09a34e87a0a91cfbd7f735cf
Autor:
Jonathan I. Silverberg, Andreas Wollenberg, Linda Stein Gold, James Del Rosso, Gil Yosipovitch, Peter Lio, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline Pierce, Helena Agell, Sonja Ständer
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2249-2260 (2024)
Abstract Introduction Lebrikizumab is a novel monoclonal antibody with established efficacy in patients with moderate-to-severe atopic dermatitis (AD) in multiple Phase 3 trials. One of the ultimate treatment goals for patients with moderate-to-sever
Externí odkaz:
https://doaj.org/article/c3b82cefa2e141b9919ea988c75ddb9e
Autor:
April W. Armstrong, H. Chih-Ho Hong, Brian M. Calimlim, Marric G. Buessing, Marjorie M. Crowell, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2457-2465 (2024)
Abstract Introduction Efficacy of upadacitinib has been assessed in trials including Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and Heads Up (NCT03738397). Measure Up 1 and 2 assessed efficacy of upadacitinib 30 mg and upadacitinib 15 mg
Externí odkaz:
https://doaj.org/article/c50f79e2bc6f4b5e8459d5588f42735c
Autor:
Carla Dias-Barbosa, Jonathan I. Silverberg, Sonja Ständer, Danielle Rodriguez, Fatoumata Fofana, Dina Filipenko, Liliana Ulianov, Christophe Piketty, Jorge Puelles
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract Background Patient-focused approaches to capturing day-to-day variability in sleep disturbance are needed to properly evaluate the sleep benefits of new treatments. Such approaches rely on patient-reported outcome (PRO) measures validated in
Externí odkaz:
https://doaj.org/article/2c5040b12c1b48b388ae5ff65f1d7703
Autor:
April W. Armstrong, Andrew F. Alexis, Andrew Blauvelt, Jonathan I. Silverberg, Claire Feeney, Mark Levenberg, Gary Chan, Fan Zhang, Luke Fostvedt
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 7, Pp 1849-1861 (2024)
Abstract Introduction Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help identify candidates for an early dose increase. A predictive model determined week 12 efficacy based on week 4 responses in patients receiving abrocit
Externí odkaz:
https://doaj.org/article/4fcba376017f4075bfd6d2381581d150
Autor:
Jonathan I. Silverberg, MD, PhD, MPH, Angel Cronin, MS, Eric A. Jones, PhD, MPH, Swapna S. Dave, MPH, MBBS, Robert R. McLean, DSc, MPH, Jeffrey Greenberg, MD, MPH, Bruce Strober, MD, PhD, Thomas Bieber, MD, PhD, MDRA, Melinda Gooderham, MSc, MD, Amy S. Paller, MD, Eric L. Simpson, MD
Publikováno v:
JAAD International, Vol 15, Iss , Pp 127-130 (2024)
Externí odkaz:
https://doaj.org/article/4aa74d6d47df4db780c150abfeeb072f